

HE Dr Bahar Idriss Abu Garda  
Minister of Health  
Federal Ministry of Health  
PO Box 303  
Khartoum,  
The Republic of Sudan

5 March 2018

***Decision Letter: Request for Gavi support for Measles follow-up campaign support***

Your Excellency,

I am writing in relation to Sudan's application for Measles follow-up campaign support, which was submitted to the Gavi Secretariat in September 2017.

Following the recommendations made by the Independent Review Committee (IRC) and clarifications provided by country, I am pleased to inform you that Gavi has **approved** Sudan's Measles follow-up campaign support application, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

Appendix A: Financial and Programmatic information – Support for Measles campaign vaccines  
Appendix B: Financial and Programmatic information – Support for Injection Safety Devices

Please do not hesitate to contact my colleague Dr Rehan Hafiz at [rhafiz@gavi.org](mailto:rhafiz@gavi.org) if you have any questions or concerns.

Yours sincerely



Hind Khatib-Othman  
Managing Director, Country Programmes

cc: The Minister of Finance  
The Director of Medical Services  
Director Planning Unit, MoH  
The EPI Manager  
WHO Country Representative  
UNICEF Country Representative  
Regional Working Group  
WHO HQ  
UNICEF Programme Division  
UNICEF Supply Division

**Decision Letter  
Sudan - Support for Measles Vaccine**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> The Republic of Sudan		
<b>2. Grant number:</b> 18-SDN-36a-X / 18-SDN-37a-Y		
<b>3. Date of Decision Letter:</b> 05/03/2018		
<b>4. Date of the Partnership Framework Agreement:</b> 10/12/2013		
<b>5. Programme title:</b> Measles follow-up campaign		
<b>6. Vaccine type:</b> Measles vaccine		
<b>7. Requested product presentation and formulation of vaccine:</b> Measles, 10 doses per vial, LYOPHILISED, Follow-up campaign		
<b>8. Programme duration<sup>1</sup>:</b> 2018		
<b>9. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement)		
	<b>2018</b>	<b>Total<sup>2</sup></b>
<b>Programme Budget (US\$)</b>	1,776,500	1,776,500
<b>10. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>3</sup>		
<b>Type of supplies to be purchased with Gavi funds in each year (Campaign)</b>	<b>2018</b>	
Number of vaccines doses	6,006,200	
<b>Annual Amounts (US\$)</b>	<b>1,776,500</b>	
<b>11. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
<b>12. Self-procurement:</b> Not applicable.		
<b>13. Co-financing obligations for routine:</b> Not applicable		
<b>14. Co-financing obligations for campaign:</b> Reference code: 18-SDN-36a-X-C The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.		
<b>Type of supplies to be purchased with Country funds in each year</b>	<b>2018</b>	
Number of vaccine doses	316,200	
Value of vaccine doses (US\$)	85,351	
<b>Total co-financing payments (US\$) (including freight)</b>	<b>93,478</b>	
<b>15. Vaccine introduction grant (in US\$):</b> Not applicable		
<b>16. Operational support for campaigns:</b> Payable up to six months before campaign.		
	<b>2018</b>	
<b>Grant amount (US\$)</b>	2,908,874	

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

**17. Additional reporting requirements:**

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points	Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool
To submit the Supplementary Immunisation Activity (SIA) technical report for Measles or Measles-Rubella campaign	Within 3 months of end of campaign
To submit the Post campaign coverage survey report for Measles or Measles-Rubella campaign	As soon as available

**18. Financial clarifications:** Not applicable.

**19. Other conditions:** As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

5 March 2018

**Decision Letter  
Sudan - Support for Injection Safety Devices**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> The Republic of Sudan					
<b>2. Grant number:</b> 17-SDN-32a-X; 18-SDN-32a-X ; 19-SDN-32a-X ; 20-SDN-32a-X					
<b>3. Date of Decision Letter:</b> 05/03/2018					
<b>4. Date of the Partnership Framework Agreement:</b> 10/12/2013					
<b>5. Programme title:</b> Injection safety devices <sup>4</sup>					
<b>6. Programme duration<sup>5</sup>:</b> 2017-2020					
<b>7. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement)					
	<b>2017</b>	2018	2019	2020	Total <sup>6</sup>
Programme Budget (US\$)	457,652	702,500	487,500	478,500	2,126,152
<b>8. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>7</sup>					
<b>TOTAL injection safety devices to be purchased with Gavi funds in each year</b>		<b>2017</b>	<b>2018</b>		
Number of AD syringes				14,589,500	
Number of re-constitution syringes				784,000	
Number of safety boxes				169,150	
<b>Annual Amounts for injection safety devices for all Gavi vaccines (US\$)</b>		<b>457,652</b>		<b>702,500</b>	
<b>Injection safety devices to be purchased with Gavi funds in each year, by type of support</b>					
<b>New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 doses per vial, LIQUID, Routine</b>				<b>2018</b>	
Number of AD syringes					761,700
Number of safety boxes					8,375
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>					<b>34,500</b>
<b>New Vaccine Support (NVS), Meningococcal type A, 10 doses per vial, LYOPHILISED, Routine</b>				<b>2018</b>	
Number of AD syringes					286,900
Number of re-constitution syringes					88,500
Number of safety boxes					4,150
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>					<b>18,000</b>

<sup>4</sup> This does not include vaccines.

<sup>5</sup> This is the entire duration of the Programme.

<sup>6</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>7</sup> The annual amount for 2017 and 2018 has been amended.

<b>New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose per vial LIQUID, Routine</b>	<b>2018</b>
Number of AD syringes	3,423,600
Number of safety boxes	37,675
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>	<b>155,500</b>
<b>New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose(s) per vial, LIQUID</b>	<b>2018</b>
Number of AD syringes	3,852,000
Number of safety boxes	42,375
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>	<b>174,500</b>
<b>New Vaccine Support (NVS), Measles, 10 doses per vial, LYOPHILISED, Follow-up campaign</b>	<b>2018</b>
Number of AD syringes	6,265,300
Number of re-constitution syringes	695,500
Number of safety boxes	76,575
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>	<b>320,000</b>
<b>9. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
<b>10. Self-procurement:</b> Not applicable	
<b>11. Co-financing obligations:</b> Co-financing requirements are listed in the relevant vaccine Decision Letter.	

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
5 March 2018